134 related articles for article (PubMed ID: 24671926)
1. Factors predictive of long-term visual outcomes of Group D eyes treated with chemoreduction and low-dose IMRT salvage: the Children's Hospital Los Angeles experience.
Berry JL; Jubran R; Wong K; Lee TC; Murphree AL; Kim JW
Br J Ophthalmol; 2014 Aug; 98(8):1061-5. PubMed ID: 24671926
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage.
Berry JL; Jubran R; Kim JW; Wong K; Bababeygy SR; Almarzouki H; Lee TC; Murphree AL
Pediatr Blood Cancer; 2013 Apr; 60(4):688-93. PubMed ID: 22997170
[TBL] [Abstract][Full Text] [Related]
3. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes.
Shields CL; Ramasubramanian A; Thangappan A; Hartzell K; Leahey A; Meadows AT; Shields JA
Ophthalmology; 2009 Mar; 116(3):544-551.e1. PubMed ID: 19157557
[TBL] [Abstract][Full Text] [Related]
4. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.
Gündüz K; Günalp I; Yalçindağ N; Unal E; Taçyildiz N; Erden E; Geyik PO
Ophthalmology; 2004 Oct; 111(10):1917-24. PubMed ID: 15465557
[TBL] [Abstract][Full Text] [Related]
5. Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors.
Shields CL; Mashayekhi A; Cater J; Shelil A; Ness S; Meadows AT; Shields JA
Arch Ophthalmol; 2005 Jun; 123(6):765-73. PubMed ID: 15955977
[TBL] [Abstract][Full Text] [Related]
6. Salvage external beam radiotherapy after failed primary chemotherapy for bilateral retinoblastoma: rate of eye and vision preservation.
Chan MP; Hungerford JL; Kingston JE; Plowman PN
Br J Ophthalmol; 2009 Jul; 93(7):891-4. PubMed ID: 19329423
[TBL] [Abstract][Full Text] [Related]
7. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation.
Schefler AC; Cicciarelli N; Feuer W; Toledano S; Murray TG
Ophthalmology; 2007 Jan; 114(1):162-9. PubMed ID: 17070578
[TBL] [Abstract][Full Text] [Related]
8. Management and outcome of retinoblastoma with vitreous seeds.
Manjandavida FP; Honavar SG; Reddy VA; Khanna R
Ophthalmology; 2014 Feb; 121(2):517-24. PubMed ID: 24572675
[TBL] [Abstract][Full Text] [Related]
9. Long-term visual outcome following chemoreduction for retinoblastoma.
Demirci H; Shields CL; Meadows AT; Shields JA
Arch Ophthalmol; 2005 Nov; 123(11):1525-30. PubMed ID: 16286614
[TBL] [Abstract][Full Text] [Related]
10. Risk of metastasis and orbital recurrence in advanced retinoblastoma eyes treated with systemic chemoreduction versus primary enucleation.
Berry JL; Kogachi K; Aziz HA; McGovern K; Zolfaghari E; Murphree AL; Jubran R; Kim JW
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 28221729
[TBL] [Abstract][Full Text] [Related]
11. [Clinical therapeutic efficiency of chemoreduction and local therapy for children with retinoblastoma].
Qian J; Xue K; Gao YJ; Yuan YF; Shan HD; Bi YW
Zhonghua Yan Ke Za Zhi; 2010 Apr; 46(4):312-6. PubMed ID: 20654057
[TBL] [Abstract][Full Text] [Related]
12. Vitreous relapse following primary chemotherapy for retinoblastoma: is adjuvant diode laser a risk factor?
Gombos DS; Cauchi PA; Hungerford JL; Addison P; Coen PG; Kingston JE
Br J Ophthalmol; 2006 Sep; 90(9):1168-72. PubMed ID: 16707528
[TBL] [Abstract][Full Text] [Related]
13. Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre.
Künkele A; Jurklies C; Wieland R; Lohmann D; Bornfeld N; Eggert A; Schulte JH
Br J Ophthalmol; 2013 Oct; 97(10):1277-83. PubMed ID: 23863458
[TBL] [Abstract][Full Text] [Related]
14. Predictors of long-term visual outcome after chemoreduction for management of intraocular retinoblastoma.
Narang S; Mashayekhi A; Rudich D; Shields CL
Clin Exp Ophthalmol; 2012; 40(7):736-42. PubMed ID: 22300311
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era.
Berry JL; Shah S; Bechtold M; Zolfaghari E; Jubran R; Kim JW
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28646513
[TBL] [Abstract][Full Text] [Related]
16. Long-term visual outcomes in intraocular retinoblastoma with eye preservation.
Batra A; Pushker N; Venkatesh P; Arora T; Tewari R; Bakhshi S
Clin Transl Oncol; 2016 Oct; 18(10):1034-8. PubMed ID: 26781471
[TBL] [Abstract][Full Text] [Related]
17. Combined chemotherapy and local treatment in the management of intraocular retinoblastoma.
Brichard B; De Bruycker JJ; De Potter P; Neven B; Vermylen C; Cornu G
Med Pediatr Oncol; 2002 Jun; 38(6):411-5. PubMed ID: 11984802
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of intravitreal chemotherapy-assisted endoresection in monocular patients with group D retinoblastoma.
Yu X; Li X; Xing Y; Lu S; Tanumiharjo S; Ma J
BMC Cancer; 2020 Aug; 20(1):808. PubMed ID: 32847550
[TBL] [Abstract][Full Text] [Related]
19. Basic understanding of current classification and management of retinoblastoma.
Shields CL; Shields JA
Curr Opin Ophthalmol; 2006 Jun; 17(3):228-34. PubMed ID: 16794434
[TBL] [Abstract][Full Text] [Related]
20. Pars plana lensectomy and intraocular lens implantation in pediatric radiation-induced cataracts in retinoblastoma.
Miller DM; Murray TG; Cicciarelli NL; Capo H; Markoe AM
Ophthalmology; 2005 Sep; 112(9):1620-4. PubMed ID: 16024083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
